-
Biogen Plunges 25% After Company Discontinues Alzheimer's Drug Study
Thursday, March 21, 2019 - 8:17am | 348Read More...Shares of neuroscience company Biogen Inc (NASDAQ: BIIB) lost more than 25 percent Thursday morning after the company said it will discontinue an ongoing Alzheimer's drug study. What Happened Biogen and its partner Japan-based Eisai said they will discontinue an ongoing global Phase 3...
-
After Biogen's Alzheimer's Update, Wall Street Reacts
Friday, July 6, 2018 - 1:27pm | 643Read More...Biogen Inc (NASDAQ: BIIB) and its Japanese partner Eisai disclosed encouraging results from an 18-month Phase 2 study of its Alzheimer's therapy BAN2401. Here's how some Street analysts reacted to the news. The Analysts Raymond James' Laura Chico maintained a Market...
-
Argus Downgrades Biogen On Trial Delays, Competition In MS, Alzheimer's Drugs
Friday, February 16, 2018 - 10:37am | 360Read More...Biogen Inc (NASDAQ: BIIB) tumbled 8 percent Wednesday after announcing a cohort expansion for its aducanumab Alzheimer’s trials — a change certain to delay results. The news, coupled with expected sales declines, has converted one analyst from an advocate to an observer. The Rating...
-
Biogen's Best-In-Class R&D Earn Makes It A Buy
Tuesday, October 17, 2017 - 11:35am | 363Read More...Analysts at Stifel turned bullish on Biogen Inc (NASDAQ: BIIB) for four key reasons. The firm's Thomas Shrader upgrades Biogen's stock from Hold to Buy with a price target boosted from $300 to $415. First, there have been no news reports on the "gigantic" aducanumab phase 3 trial, which started in...
-
Biogen's Core Business Impresses While Potential Alzheimer's Catalyst Looms
Thursday, October 5, 2017 - 10:54am | 331Read More...Analysts at Morgan Stanley turned bullish on Biogen Inc (NASDAQ: BIIB) as the company's phase 3 Alzheimer's catalyst could "make all its potential issues disappear." The firm's Matthew Harrison upgraded Biogen's stock rating from Equal-Weight to Overweight with a price target boosted from $311 to $...
-
19% Upside Predicted For Biogen, Goldman Upgrades On Strength Of Alzheimer's Drug
Wednesday, July 26, 2017 - 10:09am | 350Read More...Goldman Sachs upgraded Biogen Inc (NASDAQ: BIIB) from Neutral to Buy and raised its price target to $338 on the strength of the pharmaceutical company’s Alzheimer’s drug, Aducanumab. Analyst Terence Flynn said the drug “could now be one of the first disease-modifying drugs to...
-
Taking A Clinical Road Less Traveled: Neurotrope Hopes To Succeed In Alzheimer's Where Competitors Fail
Monday, January 30, 2017 - 3:04pm | 1344Read More...Alzheimer's has proven to be one of the most stubborn diseases known to modern medicine. An incurable, devastating illness that inspires frustration — even anger — against and from the scientific community itself, which has failed to develop new, effective therapies. Susanne...
-
Reasons To Be Optimistic On Biogen's Alzheimer's Treatment Prospects
Friday, November 25, 2016 - 11:12am | 353Read More...H.C. Wainwright said it is not surprised by Eli Lilly and Co (NYSE: LLY)’s announcement of solanezumab failing to slow the cognitive decline in Alzheimer’s Disease patients. The news is also said to be a negative for Biogen Inc (NASDAQ: BIIB), which is testing its own Alzheimer's...
-
Experts React To Concerning Alzheimer's News From Eli Lilly
Friday, November 25, 2016 - 9:39am | 445Read More...Eli Lilly and Co (NYSE: LLY) fell steeply Wednesday after it announced that its Alzheimer's disease treatment candidate solanezumab didn't meet the primary endpoint in a late-stage clinical trial dubbed EXPEDITION3. In a sympathy move, Biogen Inc (NASDAQ: BIIB) also traded notably lower. Is the...
-
Biotech Conference Suggests Tempering Expectations For Eli Lilly Drug
Tuesday, February 16, 2016 - 2:47pm | 307Read More...According to a recent note out by Leerink, investor expectations toward one of Eli Lilly and Co (NYSE: LLY)'s drugs may need to be readjusted. During a biotech conference, panelists provided updates on Lilly's solanezumab, telling investors that the drug, while likely to be approved,...
-
Piper Jaffray On Biogen Downgrade: '6 MG Data Does Not Inspire Confidence…Even More Speculative Than Before'
Wednesday, July 22, 2015 - 11:29am | 478Read More...In a report published Wednesday, Piper Jaffray analyst Joshua Schimmer downgraded shares of Biogen Inc (NASDAQ: BIIB) to Neutral from Buy with a price target lowered to $410 from a previous $485 following the company's results for the 6mg Aducanumab arm in its P2 study for Alzheimer's....
-
Disappointing Drug News Sends Biogen And XOMA Shares Down
Wednesday, July 22, 2015 - 10:34am | 560Read More...Shares of Biogen Inc (NASDAQ: BIIB) were trading lower by more than 3 percent Wednesday morning after the company reported mixed results in a Phase 1 Alzheimer's study in which a 6MG dose failed to significantly slow mental decline. "We are encouraged by these new results, which...
-
RBC Says Biogen Can Move 10% After BIIB-037 Data Is Revealed
Friday, July 10, 2015 - 12:04pm | 317Read More...Biogen Inc (NASDAQ: BIIB) is down 3 percent on Friday after commentary from Cowen. Analyst Eric Schmidt suggested investors not play the company's upcoming AAIC data reveal centered on Aducanumab, scheduled for July 22, due to a lack of conviction. It didn't take long for RBC's...
